237 related articles for article (PubMed ID: 23167246)
1. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
[TBL] [Abstract][Full Text] [Related]
2. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
3. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
[TBL] [Abstract][Full Text] [Related]
4. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
5. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
6. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
8. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
9. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract][Full Text] [Related]
10. [Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma].
Pu YQ; Zhang YP; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Nov; 41(11):869-875. PubMed ID: 38073220
[TBL] [Abstract][Full Text] [Related]
11. The management of the diaphragm during radical surgery for malignant pleural mesothelioma.
Sharkey AJ; Bilancia R; Tenconi S; Nakas A; Waller DA
Eur J Cardiothorac Surg; 2016 Aug; 50(2):311-6. PubMed ID: 27005974
[TBL] [Abstract][Full Text] [Related]
12. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
13. Cytology of malignant pleural mesothelioma: Diagnostic criteria, WHO classification updates, and immunohistochemical staining markers diagnostic value.
Shaker N; Wu D; Abid AM
Diagn Cytopathol; 2022 Nov; 50(11):532-537. PubMed ID: 36069384
[TBL] [Abstract][Full Text] [Related]
14. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
[TBL] [Abstract][Full Text] [Related]
15. The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
Kinoshita T; Ishii G; Matsumura Y; Shiozawa T; Aokage K; Hishida T; Yoshida J; Nagai K
Pathol Int; 2012 Nov; 62(11):754-7. PubMed ID: 23121607
[TBL] [Abstract][Full Text] [Related]
16. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
[TBL] [Abstract][Full Text] [Related]
17. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
[TBL] [Abstract][Full Text] [Related]
18. Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kamohara R; Hatachi G; Nagayasu T
Ann Thorac Cardiovasc Surg; 2018 Apr; 24(2):81-88. PubMed ID: 29367501
[TBL] [Abstract][Full Text] [Related]
19. Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
Hasegawa S; Kondo N; Matsumoto S; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Kamikonya N; Tsujimura T; Nakano T
Semin Thorac Cardiovasc Surg; 2019; 31(2):301-309. PubMed ID: 30639549
[TBL] [Abstract][Full Text] [Related]
20. Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
Bozzi F; Brich S; Dagrada GP; Negri T; Conca E; Cortelazzi B; Belfiore A; Perrone F; Gualeni AV; Gloghini A; Cabras A; Brenca M; Maestro R; Zaffaroni N; Casali P; Bertulli R; Deraco M; Pilotti S
Oncotarget; 2016 Nov; 7(46):75503-75517. PubMed ID: 27705913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
